Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04652765 · ClinicalTrials.gov registry record · Phase 1
Camostat With Bicalutamide for COVID-19
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04652765 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants.
The verdict
NCT04652765, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This will be a randomized, open-label study to determine if camostat+ bicalutamide decreases the proportion of people with COVID-19 who require hospitalization, compared to historical controls. Patients with symptomatic COVID-19, diagnosed as outpatients, will be randomized 1:1, stratified by gender, to treatment with standard of care alone (Arm 1) or with camostat and bicalutamide (Arm 2).
Interventions
- DRUG Camostat Mesilate
- DRUG Bicalutamide 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04652765
The ClinicalTrials.gov registry entry for NCT04652765 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Camostat Mesilate is the first listed.
NCT04652765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04652765 about?
NCT04652765 is a clinical study titled "Camostat With Bicalutamide for COVID-19". This will be a randomized, open-label study to determine if camostat+ bicalutamide decreases the proportion of people with COVID-19 who require hospitalization, compared to historical controls. Patients with symptomatic COVID-19, diagnosed as outpatients, will be randomized 1:1, stratified by gender...
What is the current status of trial NCT04652765?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-02-03. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT04652765?
The interventions under investigation include: Camostat Mesilate (DRUG), Bicalutamide 150 mg (DRUG).
Who is sponsoring clinical trial NCT04652765?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.